Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Havn Life Sciences Inc
(OP:
HAVLF
)
0.0001
UNCHANGED
Last Price
Updated: 1:06 PM EDT, Jul 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Havn Life Sciences Inc
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
July 31, 2024
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy.
Via
Benzinga
HAVN Life Closes First Tranche Of July Financing By ABO, Details On Amendments And Debt Shares Issuance
August 19, 2022
Biotech psychedelics company HAVN Life Sciences Inc. (OTC: HAVLF) recently closed the initial tranche of its financing pact with innovative fund Alpha Blue Ocean (“ABO”), previously announced on July...
Via
Benzinga
Learn About HAVN Life's New Shares Consolidation, What Changes And What Remains
August 01, 2022
A key player in the biotech-meets-psychedelics space, HAVN Life Sciences Inc.
Via
Benzinga
HAVN Life Sciences & Optimi Health Corp Announce Supply Agreements, Here Are The Details
June 28, 2022
Two publicly traded psychedelics companies announced supply agreements. HAVN Life Sciences (OTC: HAVLF) will provide mental health clinic MPB Group Inc. with psilocybin-containing mushrooms for its...
Via
Benzinga
Psyched: Cathie Wood Invests In Psychedelics Co ATAI, Bill Approved in Utah, AI Startup To 'Design States Of Mind'
February 14, 2022
The psychedelics sector received its latest sign of acceptance from Wall Street with famed investor Cathie Wood taking a position ...
Via
Benzinga
Amanita Muscaria: A Legal Psychoactive Mushroom With Potential Therapeutic Effects
April 22, 2021
Amanita Muscaria is an understudied species of psychoactive mushroom that’s as commonplace as it is misunderstood. The iconic red-c...
Via
Benzinga
HAVN Life Enters Distribution Agreement With Mycrodose Therapeutics For U.S. Market
February 10, 2022
HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP), a biotechnology company working with psychedelic compounds for investigational research to support brain health and cognitive function,...
Via
Benzinga
Havn Life Buys Subscription-Based Functional Mushroom Co. With Significant US Consumer Base
December 20, 2021
Biotech company Havn Life Sciences Inc. (CSE:HAVN) (OTC: HAVLF) is purchasing functional mushroom wellness brand Spore Life Sciences Inc. The Deal Details Under the deal...
Via
Benzinga
HAVN Life Successfully Exports Naturally Derived Psilocybin From Its Jamaica Facility Into Canada
November 23, 2021
Demonstrating the integrity of its supply chain from Jamaica into Canada, biotechnology company HAVN Life Sciences (OTCPK: HAVLF) achieved a milestone with...
Via
Benzinga
Former Tilray CEO Joins Psychedelics Company
October 07, 2021
More big names in cannabis are switching to psychedelics. Greg Engel, former CEO of Tilray (NASDAQ:
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study
September 27, 2021
The Week In Psychedelics:
Via
Benzinga
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
October 18, 2021
The Week In Psychedelics
Via
Benzinga
Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics
September 13, 2021
Last Week In Psychedelics:
Via
Benzinga
Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold
August 30, 2021
Contents
Via
Benzinga
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
October 13, 2021
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...
Via
Benzinga
Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected
August 02, 2021
Last week in Psychedelics:
Via
Benzinga
How To Invest In "Magic Mushrooms" (Psychedelics)
July 09, 2021
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest.
Via
Talk Markets
HAVN Life is Looking for a Safe Haven to Mental Health Through Psychedelic Medicine
June 10, 2021
Most companies' success stories come as a result of wanting to accomplish a greater purpose. For HAVN Life Sciences Inc. (CSE: HAVN) (OTC PINK: HAVLF) (FSE: 5NP) CEO Tim Moore...
Via
Benzinga
Psychedelic Drug Stocks Index -21% In May; Now -25% YTD
May 31, 2021
46 psychedelic drug stocks now trade on the various North American stock exchanges and the 11 with the largest market capitalizations make up the Pure-Play Psychedelic Drug Stocks Index.
Via
Talk Markets
Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public
May 17, 2021
Two of the most prominent companies in the psychedelics space released their financials for the first quarter of 2021. Compass Pa...
Via
Benzinga
Exposures
Product Safety
Psyched: Groundbreaking Phase 3 Results On MDMA, Small Pharma, Wesana Go Public, Gilgamesh Raises $27M
May 10, 2021
Last week, the psychedelics space was moved by results from the world’s first Phase 3 clinical study of a scheduled psychedelic compound...
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.